Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

To join this study, your doctors need to have confirmed you have advanced liver cancer that cannot be removed by surgery. You shouldn't have had any other drug treatments for your liver cancer yet, though you might have had other local treatments that are no longer suitable.

Your liver health and general well-being will be checked using specific scores (Child-Pugh and WHO/ECOG PS). For example, if your liver is quite healthy (Child-Pugh Class A), you might be able to join even if you're not feeling as well overall. If your liver is a bit more affected (Child-Pugh Class B), your general well-being needs to be good. Also, if you have certain types of blood clots in your liver's main blood vessel, you might still be able to join under specific conditions. You also need to have at least one spot of cancer that doctors can easily measure.

There are also some things that would mean you couldn't join. For instance, if you have other serious health problems, or if you're pregnant or breastfeeding. If you have hepatitis B or C, you'll need to be receiving treatment for it. All participants must be over 18 and weigh more than 30kg. Both men and women of childbearing potential will need to use effective birth control during the study.

If you join this study, it will involve several stages. First, there's a 'screening' period, which usually lasts up to 28 days. During this time, you'll have various tests and checks to make sure the study is right for you. If you qualify, you'll then enter the 'treatment period' where you'll receive the study medicines, durvalumab and tremelimumab, as advised by the doctors.

After you finish the main treatment, there will be two follow-up periods: a 'safety follow-up' to monitor any side effects, and a 'survival follow-up' to keep track of your health over a longer period. Throughout the study, you'll have regular hospital visits for blood tests, scans, and doctor check-ups to see how you're responding to the treatment and to manage any side effects. The exact number of visits and the total length of your participation will be explained by the study team.